Dr. Rishi P. Singh discusses the evolving management of retinal vein occlusion at Hawaiian Eye 2024. The biggest change will involve using dual therapy with faricimab after its FDA approval in 2023. Faricimab affects both angiopoietin-2 and VEGF pathways, offering new potential for patient outcomes. Singh is excited to see the results of implementing this practice in the coming year.
Source link
VIDEO: Interest high in RVO patient outcomes after faricimab treatment
